Author's response to reviews

Title: High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma

Authors:

Dongqing Lv (lvdq@enzemed.com)
Haihua Yang (yhh93181@hotmail.com)
Wei Wang (w.w11520@hotmail.com)
Youyou Xie (xieyy@enzemed.com)
Wei Hu (huw@enzemed.com)
Minhua Ye (ymh@enzemed.com)
Xiaofeng Chen (chenxf@enzemed.com)

Version: 12 Date: 25 August 2015

Author's response to reviews: see over
Re: Manuscript Number 1873641081161560 “High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma”

Date: 22-August-2015

Dear Editor,

We would like to resubmit a revised version of our manuscript (#1873641081161560) entitled “High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma” for your kind consideration for publishing in BMC Cancer as an original research article.

We thank the Editor for their constructive comments. We have responded to the criticisms (italicized in the Response) point-by-point below. Changes in the revised manuscript are formatted in blue.

We hope that the revisions have improved the manuscript to a level of quality sufficient for acceptance in BMC Cancer.

Best Regards.

Haihua Yang, M.D.

Laboratory of Cellular and Molecular Radiation Oncology
Department of Radiation Oncology
Taizhou Hospital, Wenzhou Medical University
Zhejiang Province, 317000, China
Email: yhh93181@hotmail.com
Tel: +86-138-1963-9006
Fax: +86-576-85199876
Editor's Additional Request:

1. Ethics:

Please revise the Methods section of your manuscript to include the names of the ethics committees that approved your study. We recommend the following format: This study was approved by the ethics committee of [xxx] Hospital [or University]. If more than five ethics committees approved your study, you may wish to list the names of the committees in an additional file.

*We appreciate the editor’s comment. We have modified the Methods section accordingly in the revision: lines 97-99.*

2. Consent:

Please include a statement in the manuscript to confirm whether any informed consent was required from participants or if this was waived and if so which board was responsible for the decision.

*We appreciate the editor’s comment. All patients signed the informed consent before surgery for the tissue bank of Taizhou Hospital (Figure 1 Chinese Version). As the study was based in the retrospective analyses of existing administrative and clinical data. This study was approved by the Ethics Committee of Taizhou Hospital, and tissue specimen acquisition was carried out in accordance with institutional guidelines (Figure 2 Chinese Version). We have included a statement to confirm that the all patients have signed the informed consent in the revision: lines 96-97.*

3. Please include an abbreviations section.

*We appreciate the editor’s comment. We have included the abbreviations section in the revision: lines 237-246.*

4. Please ensure that there are authors' contributions for all of the authors. We believe there is one author missing from the list.

*We appreciate the editor’s comment. We have modified the revision accordingly: lines 251and 254.*
生物样本采集知情同意书

患者姓名：
性别：\(\text{\(男\)}}\) \(\text{\(女\)}}\)
出生时间：\(\text{\(年\)}}\) \(\text{\(月\)}}\) \(\text{\(日\)}}\) \(\text{\(年\)}}\) \(\text{\(月\)}}\) \(\text{\(日\)}}\)
住院号：
临床诊断：

样本类型：所涉及的生物样本主要包括：患者手术治疗切除、清创、病理诊断后剩余的、常规焚烧处理的病侧高体组织样本及外周静脉血液样本。

样本采集目的：为进一步开展相关医学科学研究，提供研究材料，有助于提高人类肿瘤和治疗疾病的水平，减轻或解除患者病痛，提高患者生活质量。

样本采集费用：收集、处理、保存组织和血液样本，不需要被控人员承担任何费用。

捐赠者风险：病理组织采集，是在手术切除下来的病理标本上进行；血液样本采集，完全按照常规血液采集操作进行，不会对捐赠者的身体造成损伤和不良影响。

隐私保护：捐赠者的所有个人资料均保密，所有样本均将严格匿名使用，研究者不会获得任何有关个人隐私的资料信息，研究结果可能在学术会议或期刊上公开发表，但是捐赠者的姓名决不会出现在上述任何发表的资料中。

捐赠者权利：捐赠者可以选择自愿参与相关的医学科学研究，也可以选择不参与或参与后随时退出。如果任何理由，无论选择自愿参与、不参与、或者选择参与后退出，都不会因此而影响疾病的诊断和治疗。样本保存有效期为十年，有效期之后将按照相关规程进行销毁处理。


作为一名患者，我在充分了解上述样本采集知情同意内容后，自愿参加相关疾病的医学科学研究。

患者或家属签名：
医生签名：

\(\text{\(年\)}}\) \(\text{\(月\)}}\) \(\text{\(日\)}}\) \(\text{\(年\)}}\) \(\text{\(月\)}}\) \(\text{\(日\)}}\)
关于浙江省医药卫生科技计划“新抑癌基因 PHLPP 在非小细胞肺癌中的作用及机制研究”涉及人体相关研究内容的审查意见

我院吕冬春主任医师申请的“新抑癌基因 PHLPP 在非小细胞肺癌中的作用及机制研究”所涉及的人体组织相关研究内容，经浙江省台州医院伦理委员会审查，符合国家及浙江省台州医院医学研究伦理有关章程，可以实施。